Government-Owned Inventions; Availability for Licensing, 52805-52806 [E6-14832]

Download as PDF Federal Register / Vol. 71, No. 173 / Thursday, September 7, 2006 / Notices the gene product or post-translational levels. Development Status: (1) The microarrays’ performance was tested by proteomic profiling of two NCI–60 cancer cell lines (Renal UO–31 and Leukemia HL–60), demonstrating a high level of reproducibility. (2) The microarrays’ performance was further evaluated by analysis of the protein expression profiles of 12 Borderline ovarian and 9 Adenocarcinoma ovarian tumors using normal ovarian surface epithelial cells as a reference cell line. It was possible to detect 77 proteins that showed statistically significant (p<0.05) differences distinguishing Borderline tumors and Adenocarcinoma tumors, demonstrating that the novel microarrays described are useful tools for proteomics. Inventors: Cassio S. Baptista, Lionel Best, David J. Munroe (NCI). Patent Status: U.S. Provisional Application No. 60/797,301 filed 02 May 2006 (HHS Reference No. E–207– 2006/0–US–01). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: Cristina Thalhammer-Reyero, PhD, MBA; 301/ 435–4507; thalhamc@mail.nih.gov. Collaborative Research Opportunity: The NCI-Laboratory of Molecular Technology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this novel monoclonal antibody microarray. Please contact Betty Tong, PhD at 301–594–4263 or tongb@mail.nih.gov for more information. Dated: August 31, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6–14831 Filed 9–6–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. rwilkins on PROD1PC63 with NOTICES AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious VerDate Aug<31>2005 18:11 Sep 06, 2006 Jkt 208001 commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Methods for Enhancing Beta Cell Function in Diabetes Description of Technology: Diabetes results when beta cell performance is compromised through loss of cells or by reduced cell function. Anti-diabetic drugs that stimulate insulin production, such as sulfonylureas and meglitinides, have limited efficacy when beta cell responsiveness is deficient. There exists a critical need, therefore, for new diagnostics and therapeutics that focus on beta cell responsiveness in diabetes. This technology describes methods for improving pancreatic endocrine function and delaying the onset of diabetes by enhancing beta cell function using ligands and/or regulators of Notch receptors. These methods are directed not only to mature beta cells, but to immature beta cells and to beta cells formed from differentiation of stem cells. This technology also describes isolated pancreatic progenitor cells, and offers an effective method for identifying and isolating these cells using Notch receptor markers. Applications: (1) Treatment for diabetes that enhances beta cell function or replaces lost beta cells; (2) Isolation and expansion of pancreatic progenitor cells for diabetes therapy; (3) Diagnostic test to monitor beta cell function Market: (1) Over 20 million people suffer from diabetes in the United States, and approximately 170 million people are affected worldwide. (2) There are an estimated 6.2 million undiagnosed cases of diabetes in the United States. Development Status: Pre-clinical data are available. Inventors: Josephine M. Egan, et al. (NIA). Patent Status: U.S. Provisional Application No. 60/590,281 filed 22 Jul 2004 (HHS Reference No. E–262–2003/ 0–US–01); PCT Application No. PCT/ US2005/026207 filed 22 Jul 2005, which PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 52805 published as WO 2006/023209 on 02 Mar 2006 (HHS Reference No. E–262– 2003/0–PCT–02). Licensing Status: Available for exclusive or non-exclusive licensing. Licensing Contact: Tara L. Kirby, Ph.D.; 301/435–4426; tarak@mail.nih.gov. A Nurr1-Knockout Mouse Model for Parkinson’s Disease and Stem Cell Differentiation Description of Technology: The researchers have generated Nurr1knockout mice via genomic locus inactivation using homologous recombination. Transcription factor Nurr1 is an obligatory factor for neurotransmitter dopamine biosynthesis in ventral midbrain. From a neurological and clinical perspective, it suggests an entirely new mechanism for dopamine depletion in a region where dopamine is known to be involved in Parkinson’s disease. Activation of Nurr1 may be therapeutically useful for Parkinson’s disease patients; therefore, the mice would be useful in Parkinson’s disease research. Additionally, Nurr1 has been shown to be critical for development of midbrain dopaminergic neurons, and thus may contribute to stem cell-based therapies for neurological disorders. Nurr1 is also important for osteoblast differentiation, suggesting a general role in stem cell differentiation and growth. Applications: (1) Research and drug testing for Parkinson’s disease and other neurological disorders; (2) Stem cell research relating to neurological and other disorders and bone formation. Inventor: Dr. Vera Nikodem (NIDDK). Relevant Publication: SO Castillo, JS Baffi, M Palkovits, DS Goldstein, IJ Kopin, J Witta, MA Magnuson, VM Nikodem. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol Cell Neurosci. 1998 May, 11(1– 2):36–46. Related Publications: 1. MK Lee, H Choi, M Gil, VM Nikodem. Regulation of osteoblast differentiation by Nurr1 in MC3T3-E1 cell line and mouse calvarial osteoblasts. J Cell Biochem. 2006 June 1 [Epub ahead of print, doi:10.1002/ jcb.20990]. 2. J Jankovic, S Chen, WD Le. The role of Nurr1 in the development of dopaminergic neurons and Parkinson’s disease. Prog Neurobiol. 2005 Sep-Oct, 77(1–2):128–138. Epub 2005 Oct 21, doi:10.1016/j.pneurobio.2005.09.001. E:\FR\FM\07SEN1.SGM 07SEN1 52806 Federal Register / Vol. 71, No. 173 / Thursday, September 7, 2006 / Notices Patent Status: HHS Reference No. E– 024–1999/0—Research Tool. Licensing Status: This technology is available under a Biological Materials License. Licensing Contact: Tara L. Kirby, Ph.D.; 301/435–4426; tarak@mail.nih.gov. Dated: August 31, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6–14832 Filed 9–6–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Child Health and Human Development; Notice of Closed Meetings rwilkins on PROD1PC63 with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Health and Human Development Special Emphasis Panel; Graduate Training in Demography. Date: September 19, 2006. Time: 12 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Michele C. HindiAlexander, PhD, Division of Scientific Review, National Institutes of Health, National Institute for Child Health and Human Development, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20812–7510, (301) 435–8382, hindialm@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Love, Money and a Dad for my Kids: Low Income Women and Marriage. VerDate Aug<31>2005 18:11 Sep 06, 2006 Jkt 208001 Date: September 21, 2006. Time: 12 p.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Michele C. HindiAlexander, PhD, Division of Scientific Review, National Institutes of Health, National Institute for Child Health and Human Development, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20812–7510, (301) 435–8382, hindialm@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Contact Person: Paul A. Amstad, PhD, Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/ NIAID/DHHS, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–402– 7098, pamstad@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 30, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–7463 Filed 9–6–06; 8:45am] National Institute on Deafness and Other Communication Disorders; Notice of Meeting BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Collaborative Network for Clinical Research on Immune Tolerance. Date: September 25, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate contract proposals. Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007. PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 Dated: August 30, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–7465 Filed 9–6–06; 8:45am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDCD. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute on Deafness and Other Communication Disorders, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIDCD. Date: October 27, 2006. Open: 7:30 a.m. to 8:15 a.m. Agenda: Reports from Institute staff. Place: National Institutes of Health, 5 Research Court, 1A07, Rockville, MD 20850. Closed: 8:15 a.m. to 3 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, 5 Research Court, 1A07, Rockville, MD 20850. E:\FR\FM\07SEN1.SGM 07SEN1

Agencies

[Federal Register Volume 71, Number 173 (Thursday, September 7, 2006)]
[Notices]
[Pages 52805-52806]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-14832]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Methods for Enhancing Beta Cell Function in Diabetes

    Description of Technology: Diabetes results when beta cell 
performance is compromised through loss of cells or by reduced cell 
function. Anti-diabetic drugs that stimulate insulin production, such 
as sulfonylureas and meglitinides, have limited efficacy when beta cell 
responsiveness is deficient. There exists a critical need, therefore, 
for new diagnostics and therapeutics that focus on beta cell 
responsiveness in diabetes.
    This technology describes methods for improving pancreatic 
endocrine function and delaying the onset of diabetes by enhancing beta 
cell function using ligands and/or regulators of Notch receptors. These 
methods are directed not only to mature beta cells, but to immature 
beta cells and to beta cells formed from differentiation of stem cells. 
This technology also describes isolated pancreatic progenitor cells, 
and offers an effective method for identifying and isolating these 
cells using Notch receptor markers.
    Applications: (1) Treatment for diabetes that enhances beta cell 
function or replaces lost beta cells; (2) Isolation and expansion of 
pancreatic progenitor cells for diabetes therapy; (3) Diagnostic test 
to monitor beta cell function
    Market: (1) Over 20 million people suffer from diabetes in the 
United States, and approximately 170 million people are affected 
worldwide. (2) There are an estimated 6.2 million undiagnosed cases of 
diabetes in the United States.
    Development Status: Pre-clinical data are available.
    Inventors: Josephine M. Egan, et al. (NIA).
    Patent Status: U.S. Provisional Application No. 60/590,281 filed 22 
Jul 2004 (HHS Reference No. E-262-2003/0-US-01); PCT Application No. 
PCT/US2005/026207 filed 22 Jul 2005, which published as WO 2006/023209 
on 02 Mar 2006 (HHS Reference No. E-262-2003/0-PCT-02).
    Licensing Status: Available for exclusive or non-exclusive 
licensing.
    Licensing Contact: Tara L. Kirby, Ph.D.; 301/435-4426; 
tarak@mail.nih.gov.

A Nurr1-Knockout Mouse Model for Parkinson's Disease and Stem Cell 
Differentiation

    Description of Technology: The researchers have generated Nurr1-
knockout mice via genomic locus inactivation using homologous 
recombination.
    Transcription factor Nurr1 is an obligatory factor for 
neurotransmitter dopamine biosynthesis in ventral midbrain. From a 
neurological and clinical perspective, it suggests an entirely new 
mechanism for dopamine depletion in a region where dopamine is known to 
be involved in Parkinson's disease. Activation of Nurr1 may be 
therapeutically useful for Parkinson's disease patients; therefore, the 
mice would be useful in Parkinson's disease research.
    Additionally, Nurr1 has been shown to be critical for development 
of midbrain dopaminergic neurons, and thus may contribute to stem cell-
based therapies for neurological disorders. Nurr1 is also important for 
osteoblast differentiation, suggesting a general role in stem cell 
differentiation and growth.
    Applications: (1) Research and drug testing for Parkinson's disease 
and other neurological disorders; (2) Stem cell research relating to 
neurological and other disorders and bone formation.
    Inventor: Dr. Vera Nikodem (NIDDK).
    Relevant Publication: SO Castillo, JS Baffi, M Palkovits, DS 
Goldstein, IJ Kopin, J Witta, MA Magnuson, VM Nikodem. Dopamine 
biosynthesis is selectively abolished in substantia nigra/ventral 
tegmental area but not in hypothalamic neurons in mice with targeted 
disruption of the Nurr1 gene. Mol Cell Neurosci. 1998 May, 11(1-2):36-
46.
    Related Publications:
    1. MK Lee, H Choi, M Gil, VM Nikodem. Regulation of osteoblast 
differentiation by Nurr1 in MC3T3-E1 cell line and mouse calvarial 
osteoblasts. J Cell Biochem. 2006 June 1 [Epub ahead of print, 
doi:10.1002/jcb.20990].
    2. J Jankovic, S Chen, WD Le. The role of Nurr1 in the development 
of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005 
Sep-Oct, 77(1-2):128-138. Epub 2005 Oct 21, doi:10.1016/
j.pneurobio.2005.09.001.

[[Page 52806]]

    Patent Status: HHS Reference No. E-024-1999/0--Research Tool.
    Licensing Status: This technology is available under a Biological 
Materials License.
    Licensing Contact: Tara L. Kirby, Ph.D.; 301/435-4426; 
tarak@mail.nih.gov.

    Dated: August 31, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer,Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E6-14832 Filed 9-6-06; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.